Neurocrine Biosciences, Inc.
NBIXNASDAQHealthcare● Active
$163.73
$-0.15(-0.09%)
Market Cap$16.5B
P/E Ratio—
52W High$168
52W Low$122.14
Neurocrine Biosciences, Inc. (NBIX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NBIX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Cost of Revenue | $0.05B | $0.03B | $0.04B | $0.02B | $0.01B |
| Gross Profit | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B |
| Gross Margin %(computed) | 98.18% | 98.56% | 97.90% | 98.44% | 98.74% |
| Operating Expenses | |||||
| R&D Expenses | $1.02B | $0.73B | $0.56B | $0.46B | $0.33B |
| G&A Expenses | $0.00B | $0.82B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $2.19B | $1.75B | $1.60B | $1.22B | $1.02B |
| Operating Income | $0.62B | $0.57B | $0.25B | $0.25B | $0.10B |
| Operating Margin %(computed) | 21.64% | 24.22% | 13.30% | 16.73% | 9.04% |
| Interest Income | $0.09B | $0.09B | $0.00B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.13B | $0.00B | $0.01B | $0.03B |
| Income Before Tax | $0.71B | $0.49B | $0.33B | $0.21B | $0.10B |
| Income Tax Expense | $0.23B | $0.14B | $0.08B | $0.06B | $0.01B |
| Net Income | $0.48B | $0.34B | $0.25B | $0.15B | $0.09B |
| Net Margin %(computed) | 16.73% | 14.49% | 13.23% | 10.38% | 7.90% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 |
| Wtd Avg Shares | 0.10B | 0.10B | 0.10B | 0.10B | 0.09B |
| EBITDA | $0.67B | $0.64B | $0.42B | $0.26B | $0.14B |
| EBITDA Margin %(computed) | 23.30% | 27.16% | 22.05% | 17.77% | 12.18% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Neurocrine Biosciences, Inc. data
About Neurocrine Biosciences, Inc. (NBIX) Income Statement
Neurocrine Biosciences, Inc. (NBIX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NBIX reported revenue of $2.86B, gross profit of $2.81B (gross margin 98.18%), and net income of $0.48B — a net profit margin of 16.73%.
Frequently asked questions
NBIX · 4 questionsNeurocrine Biosciences, Inc. (NBIX) reported revenue of $2.86B for 2025, up 21.4% year-over-year.
NBIX revenueNBIX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08